PRGO | Ticker Profile - Titan Protect

PRGO

Perrigo Company plc

Healthcare · Drug Manufacturers - Specialty & Generic · NYQ

$10.83

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.5B

Total market value of the company

Trailing P/E

N/A

Forward P/E

4.72

Based on estimated future earnings — lower means cheaper

Rev Growth

-7.2%

Year-over-year revenue change

Profit Margin

-43.5%

How much profit the company keeps from each dollar of revenue

ROE

-52.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$16.00

+48% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 4 analysts covering this stock

About Perrigo Company plc

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

https://www.perrigo.com

Country: Ireland Employees: 8,100 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.746

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0746

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.486

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-32.5%

Historical annualised return based on price data

Max Drawdown

-66.8%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.54

Less volatile than the market — more defensive

52W High

$28.44

62% below the year high

52W Low

$9.23

17% above the year low

Avg Volume

3,212,586

Average daily shares traded — higher means easier to buy and sell

Short Ratio

6.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

16.0%

Elevated short interest — bears are positioned against this

Div Yield

1,039.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$-13.36

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

153.22

Heavy leverage — higher financial risk if revenues decline

Current Ratio

2.72

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

1.09

Like current ratio but excludes inventory — stricter test

Gross Margin

34.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

3.5%

Profit from core operations before interest and tax

Free Cash Flow

$108M

Positive — the business generates more cash than it spends

Revenue (TTM)

$4.2B

Total revenue over the last 12 months

Net Income

$-1,792,300,032

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$20.00

Target Median

$16.00

Target Low

$14.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go